Home » Newsletters » BioWorld Science

BioWorld Science

March 23, 2021

View Archived Issues

Terns initiates dosing in first-in-human trial of TERN-501

Odonate Therapeutics discontinues development of tesetaxel

Encouraging preliminary phase I data for RP-L301 in pyruvate kinase deficiency

BioCryst presents successful data from proof-of-concept trial of BCX-9930 in PNH

FDA approves IND application for CBX-12

Avalon Globocare and MIT expand their codevelopment program

Evotec and Takeda enter multi-RNA target alliance

GRAd-COV2 vaccine candidate enters phase II/III development

CaaMTech patents new ammonium tryptamines for pain

Roche discloses HBeAg and HBsAg secretion inhibitors

Terns identifies thyroid hormone receptor beta agonists

Incyte synthesizes adenosine A2A and/or A2B receptor antagonists

Headless hemagglutinin makes for broad-spectrum flu vaccine

Updated results from ongoing phase I/II MATINS study of bexmarilimab

New anti-CD19 antibodies presented by Viela Bio

SOV-2012-F1, oral testosterone formulation that improves patient satisfaction scores

Tildacerfont: 12-week extension study data presented in patients with CAH

Genentech ends dosing in phase III study of tominersen for Huntington's disease

Akero reports phase IIa data on efruxifermin in patients with cirrhotic NASH

European grant supports consortium's development of mRNA for HPV16-positive cancers

FDA approves Zegalogue to treat severe hypoglycemia in children and adults with diabetes

CanSino reports China NMPA clearance of clinical trial application for inhaled COVID-19 vaccine

Regeneron reports topline phase III data on REGEN-COV in nonhospitalized COVID-19 patients

Japanese approval of Arikayce for NTM lung disease caused by MAC

Daiichi Sankyo's mRNA vaccine for COVID-19 enters phase I/II trial in Japan

Phase III VISION study of 177Lu-PSMA-617 meets primary endpoints in CRPC

Keytruda wins FDA approval for esophageal or GEJ carcinoma

Japanese MHLW approves Pemazyre for unresectable biliary tract cancer with FGFR2 fusion gene

Frequency Therapeutics reports phase IIa data on FX-322 in sensorineural hearing loss

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 15, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
LINC01116 has prognostic value in lung cancer, study shows
BioWorld MedTech
Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...